Entrada Therapeutics price target raised to $28 from $25 at Oppenheimer
The Fly

Entrada Therapeutics price target raised to $28 from $25 at Oppenheimer

Oppenheimer raised the firm’s price target on Entrada Therapeutics (TRDA) to $28 from $25 and keeps an Outperform rating on the shares. The firm notes Entrada’s Q3 top line of $19.6M and bottom line of (35c) beat both its and the Street’s estimates. As teh company remains focused on its development programs, Oppenheimer remains pleased by the recent preliminary positive data from the Phase 1 ENTR-601-44-101 for DMD.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App